Catalyst Pharmaceuticals, Inc.

DB:CN2 Stock Report

Market Cap: €2.4b

Catalyst Pharmaceuticals Past Earnings Performance

Past criteria checks 6/6

Catalyst Pharmaceuticals has been growing earnings at an average annual rate of 19%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 34.8% per year. Catalyst Pharmaceuticals's return on equity is 21.6%, and it has net margins of 31%.

Key information

19.0%

Earnings growth rate

17.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate34.8%
Return on equity21.6%
Net Margin31.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Catalyst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CN2 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244601431760
30 Jun 24434681630
31 Mar 24411651510
31 Dec 23398711340
30 Sep 23348621060
30 Jun 23303116860
31 Mar 2325699700
31 Dec 2221483570
30 Sep 2219267560
30 Jun 2217054550
31 Mar 2215445530
31 Dec 2114139500
30 Sep 2113442500
30 Jun 2112775480
31 Mar 2112072470
31 Dec 2011975440
30 Sep 2011871420
30 Jun 2012042400
31 Mar 2011943390
31 Dec 1910232370
30 Sep 19739320
30 Jun 1942-12280
31 Mar 1913-29220
31 Dec 181-34160
30 Sep 180-25110
30 Jun 180-2190
31 Mar 180-1980
31 Dec 170-1870
30 Sep 170-1760
30 Jun 170-1760
31 Mar 170-186-4
31 Dec 160-1870
30 Sep 160-2094
30 Jun 160-2097
31 Mar 160-20913
31 Dec 150-2090
30 Sep 150-18810
30 Jun 150-18710
31 Mar 150-17610
31 Dec 140-16410
30 Sep 140-13410
30 Jun 140-14310
31 Mar 140-14210

Quality Earnings: CN2 has high quality earnings.

Growing Profit Margin: CN2's current net profit margins (31%) are higher than last year (17.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CN2's earnings have grown by 19% per year over the past 5 years.

Accelerating Growth: CN2's earnings growth over the past year (130.2%) exceeds its 5-year average (19% per year).

Earnings vs Industry: CN2 earnings growth over the past year (130.2%) exceeded the Biotechs industry -18.2%.


Return on Equity

High ROE: CN2's Return on Equity (21.6%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 20:07
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Catalyst Pharmaceuticals, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Jason Matthew GerberryBofA Global Research
Charles DuncanCantor Fitzgerald & Co.